- Home
- YRD vs LCTX Comparison
YRD vs LCTX Comparison
Compare YRD & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | YRD | LCTX |
|---|---|---|
| Founded | 2012 | 1990 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.8M | 366.2M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | YRD | LCTX |
|---|---|---|
| Price | $3.83 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 58.3K | ★ 1.1M |
| Earning Date | 03-19-2026 | 03-09-2026 |
| Dividend Yield | ★ 11.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.03 | N/A |
| Revenue | ★ $872,820,262.00 | $10,816,000.00 |
| Revenue This Year | N/A | $6.32 |
| Revenue Next Year | N/A | $124.49 |
| P/E Ratio | $1.88 | ★ N/A |
| Revenue Growth | 10.41 | ★ 24.05 |
| 52 Week Low | $3.64 | $0.37 |
| 52 Week High | $8.74 | $2.09 |
Technical Indicators
Market Signals| Indicator | YRD | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 51.44 |
| Support Level | $3.80 | $1.45 |
| Resistance Level | $4.15 | $1.80 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 14.55 | 65.71 |
Price Performance
Historical ComparisonAbout YRD Yiren Digital Ltd.
Yiren Digital Ltd is an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.